CareDx Is Maintained at Buy by Craig-Hallum

CareDx Is Maintained at Buy by Craig-Hallum

Dow JonesMay 17 20:19

Analysts Offer Insights on Healthcare Companies: CareDx (CDNA), Amgen (AMGN) and Orasure Technologies (OSUR)

TipRanksMay 17 20:11

Craig-Hallum: Maintaining the CaredX (CDNA.US) rating, adjusted from buy to buy rating, and adjusted the target price from $15.00 to $22.00.

Craig-Hallum: Maintaining the CaredX (CDNA.US) rating, adjusted from buy to buy rating, and adjusted the target price from $15.00 to $22.00.

Zhitong FinanceMay 17 20:10

Craig-Hallum Maintains Buy on CareDx, Raises Price Target to $22

Craig-Hallum analyst Connor Chamberlain maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $15 to $22.

BenzingaMay 17 20:09

Landmark Study Shows CareDx's HeartCare Outperforms Dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes With Fewer Biopsies

HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular Rejection Cardiologists Performed the Fewest Biopsies After Dual Negative HeartCare Results Compared to Single or Dual Positive

BusinesswireMay 17 04:05

HC Wainwright & Co. Reiterates Neutral on CareDx

HC Wainwright & Co. analyst Yi Chen reiterates CareDx with a Neutral.

Analyst UpgradesMay 15 23:32